Figure 5From: Correlation between NK function and response to trastuzumab in metastatic breast cancer patientsGlobal time to tumor progression at twelve months. The Kaplan-Meier PFS curve shows that the percentage of progression-free patients is 75% at six months from start of Trastuzumab therapy and declines to 50% at twelve months.Back to article page